A Study on the Efficacy of Immunotherapy, the Occurrence and Severity of Adverse Reactions in Patients with Non-small Cell Lung Cancer in High-altitude Areas

Inclusion Criteria: * (1) Patients with primary non-small cell lung cancer (adenocarcinoma/squamous cell carcinoma/adenosquamous cell carcinoma/large cell lung cancer/others) with clear cellular/histopathological evidence; (2) Primary non-small cell lung cancer of any stage receiving immunotherapy for the first time; (3) Patients who have undergone at least 2 cycles of immunotherapy during the treatment period and have undergone one efficacy evaluation; (4) Patients with at least one evaluable target lesion (except for those with uncontrolled brain metastases) according to Response Evaluation Criteria for Solid T Tumors (RECIST, version 1.1); (5) Voluntary participation in research and strong willingness to cooperate; (6) has been residing in Qinghai Province since birth; (7) Have been residing in Shaanxi Province since birth; (8) Be at least 18 years old; Exclusion Criteria: 1. Patients with unknown histopathological type were excluded; 2. Patients with unclear diagnosis and treatment information and immunotherapy-related adverse reactions; 3. Patients with bipolar/multiple primary non-small cell lung cancer with other tumors were excluded; 4. Patients who are unwilling to join the study and have poor willingness to cooperate; 5. Patients who migrated to Qinghai or Shaanxi from different altitudes and had a history of migration between the two provinces were excluded; 6. exclude patients with a history of emigration from parents; 7. Patients who have received immunotherapy for other tumors in the past; 8. Prior immunosuppressive therapy prior to exclusion